SCHEMBL2567010

SCHEMBL2567010

CCOC(=O)c1cnc(-n2cccn2)nc1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 4/20 0.44
TP53 P04637 4/20 0.44
TSHR P16473 3/20 0.44
NPSR1 Q6W5P4 3/20 0.44
JAK2 O60674 1/20 0.44
JAK3 P52333 1/20 0.44
MAPT P10636 4/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
USP2 O75604 1/20 0.43
ALDH1A1 P00352 9/20 0.41
KDM4E B2RXH2 7/20 0.41
HPGD P15428 6/20 0.41
NPC1 O15118 5/20 0.41
HSD17B10 Q99714 4/20 0.41
RAB9A P51151 4/20 0.41
LMNA P02545 2/20 0.41
PDE4A P27815 1/20 0.41
MAPK1 P28482 1/20 0.41
ATM Q13315 1/20 0.41
RECQL P46063 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16243463 0.99 ALOX15 (0.43) ALOX15TP53TSHRNPSR1JAK2
SCHEMBL22573751 0.86 RAB9A (0.53) TP53TSHRJAK2JAK3MAPT
SCHEMBL16243464 0.85 ALOX15 (0.42) ALOX15TP53TSHRNPSR1JAK2
SCHEMBL12929627 0.84 ALDH1A1 (0.59) ALOX15TP53TSHRNPSR1JAK2
SCHEMBL12294434 0.82 NPC1 (0.43) ALOX15TP53TSHRNPSR1JAK2
SCHEMBL2579081 0.80 NMT1 (0.46) ALOX15TP53TSHRNPSR1MAPT
SCHEMBL1819465 0.80 LMNA (0.49) NPSR1MAPTALDH1A1KDM4ELMNA
SCHEMBL20098307 0.79 ALOX15 (0.63) ALOX15TP53TSHRMAPTSMN1; SMN2
SCHEMBL14809669 0.79 ALOX15 (0.48) ALOX15TP53TSHRNPSR1MAPT
SCHEMBL28382840 0.79 ALDH1A1 (0.42) MAPTSMN1; SMN2USP2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109232541-A Prolyl hydroxylase and histon deacetylase (HDAC) double inhibitor and its preparation method and application 中国医学科学院放射医学研究所 2019-01-18 CN disclosed
EP-2758059-B1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME (US) 2018-10-24 EP disclosed
EP-2560655-B1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME (US) 2016-08-24 EP disclosed
US-9079930-B2 Substituted pyrimidines MERCK SHARP & DOHME CORP. (US) 2015-07-14 US disclosed
US-9079930-B2 Substituted pyrimidines MERCK SHARP & DOHME CORP. (US) 2015-07-14 US disclosed
US-9079930-B2 Substituted pyrimidines MERCK SHARP & DOHME CORP. (US) 2015-07-14 US disclosed
US-9006433-B2 Substituted pyrimidines MERCK SHARP & DOHME CORP. (US) 2015-04-14 US disclosed
US-9006433-B2 Substituted pyrimidines MERCK SHARP & DOHME CORP. (US) 2015-04-14 US disclosed
US-9006433-B2 Substituted pyrimidines MERCK SHARP & DOHME CORP. (US) 2015-04-14 US disclosed
US-20140349972-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME CORP (US) 2014-11-27 US disclosed
EP-2758059-A1 SUBSTITUTED PYRIMIDINES Merck Sharp & Dohme Corp. (US) 2014-07-30 EP disclosed
WO-2013043624-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME CORP. (US) 2013-03-28 WO disclosed
WO-2013043624-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME CORP. (US) 2013-03-28 WO disclosed
WO-2013040790-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME CORP. (US) 2013-03-28 WO disclosed
WO-2013040790-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME CORP. (US) 2013-03-28 WO disclosed
EP-2560655-A1 SUBSTITUTED PYRIMIDINES Merck Sharp & Dohme Corp. (US) 2013-02-27 EP disclosed
US-20130018053-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME LLC 2013-01-17 US disclosed
US-20130018053-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME LLC 2013-01-17 US disclosed
WO-2011133444-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME CORP. (US) 2011-10-27 WO disclosed
WO-2011130908-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME CORP. (US) 2011-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018053-A1 SUBSTITUTED PYRIMIDINES HIF1AN, HIF1A, EGLN3 ALOX15 1753/4885TP53 692/4885TSHR 2794/4885
US-20140349972-A1 SUBSTITUTED PYRIMIDINES HIF1AN, HIF1A, EGLN3 ALOX15 1753/4885TP53 692/4885TSHR 2794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.